Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupropion + nicotine + cognitive behavioral therapy
- Development stage
- Unknown
- Lead developer
- National Institute on Drug Abuse
- Modality
- Small Molecules
- Administration
- Oral, Transdermal
01
Overview
This combination therapy approach was evaluated in a Phase 4 clinical trial (NIDA 5R01DA011512) for the treatment of tobacco use disorder in individuals with unipolar depression. The regimen consists of **bupropion sustained-release (SR)**, a small molecule antidepressant that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and a non-competitive antagonist at nicotinic acetylcholine receptors; **transdermal nicotine replacement therapy (nicotine patch)**, which provides a steady delivery of nicotine to stimulate nicotinic receptors and mitigate withdrawal; and **cognitive behavioral therapy (CBT)**, a behavioral intervention designed to address the psychological components of addiction and manage abstinence-associated depressive symptoms. The study aimed to determine if the addition of bupropion to standard nicotine replacement and behavioral support would improve long-term abstinence rates in smokers with a history of or current unipolar depressive disorder.
- Brand names
- ZybanWellbutrin SRNicoderm CQ
- Other names
- Pharmacotherapies for Smoking CessationBupropion with Nicotine Patch and CBT for Smoking Cessation in Depressed Individualsbupropion sustained-release + transdermal nicotine replacement therapy + cognitive behavioral therapy
02
Targets
DAT (Dopamine plasma membrane transport protein)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on bupropion + nicotine + cognitive behavioral therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupropion + nicotine + cognitive behavioral therapy.